HowellOWReevesCANicholasRet al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain2011; 134: 2755–2771.
2.
AbsintaMVuoloLRaoAet al. Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis. Neurology2015; 85: 18–28.
3.
EiselePGriebeMSzaboKet al. Investigation of leptomeningeal enhancement in MS: A postcontrast FLAIR MRI study. Neurology2015; 84: 770–775.
4.
ZivadinovRRamasamyDPHagemeierJet al. Evaluation of leptomeningeal contrast enhancement using pre-and postcontrast subtraction 3D-FLAIR imaging in multiple sclerosis. AJNR Am J Neuroradiol2018; 39: 642–647.
5.
ZurawskiJLassmannHBakshiR.Use of magnetic resonance imaging to visualize leptomeningeal inflammation in patients with multiple sclerosis: A review. JAMA Neurol2017; 74: 100–109.
6.
Pino-LopezLWenzHBöhmeJet al. Contrast-enhanced fat-suppressed FLAIR for the characterization of leptomeningeal inflammation in optic neuritis. Mult Scler. Epub ahead of print 1 April 2018. DOI: 10.1177/1352458518770268.
7.
HarrisonDMWangKYFiolJet al. Leptomeningeal enhancement at 7T in multiple sclerosis: Frequency, morphology, and relationship to cortical volume. J Neuroimaging2017; 27: 461–468.
8.
ZivadinovRRamasamyDPVaneckovaMet al. Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Mult Scler2017; 23: 1336–1345.
9.
MakshakovGMagonovETotolyanNet al. Leptomeningeal contrast enhancement is associated with disability progression and grey matter atrophy in multiple sclerosis. Neurol Res Int2017; 2017: 8652463.
10.
AbsintaMCorteseICVuoloLet al. Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases. Neurology2017; 88: 1439–1444.
11.
AsgariNFlanaganEPFujiharaKet al. Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm2017; 4(4): e343.
12.
RoviraÀWattjesMPTintoréMet al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol2015; 11: 471–482.
13.
WattjesMPRoviraÀMillerDet al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—Establishing disease prognosis and monitoring patients. Nat Rev Neurol2015; 11: 597–606.
14.
KooiEJGeurtsJJvan HorssenJet al. Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis. J Neuropathol Exp Neurol2009; 68: 1021–1028.
15.
KilsdonkIDSchoonheimMWattjesMP.In-vivo imaging of meningeal inflammation in multiple sclerosis: Presence of evidence or evidence of presence?Mult Scler2017; 23: 1169–1171.
